144060-79-7

Basic information

• Product Name: 2-(3-bromo-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester
• Synonyms: 2-(3-bromo-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester
• CAS NO: 144060-79-7
• Molecular Weight: 342.213
• Mol File: 144060-79-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(3-bromo-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-bromo-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester(144060-79-7)
• EPA Substance Registry System: 2-(3-bromo-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester(144060-79-7)

Safety Data

• Hazardous Substances Data: 144060-79-7(Hazardous Substances Data)

Upstream product

• 2973-78-6 3-bromo-4-hydroxybenzylaldehyde 
• 2315-86-8 3-bromo-4-hydroxybenzonitrile 
• 25984-64-9 3-bromo-4-hydroxy-thiobenzamide 
• 609-15-4 ethyl 2-chloro-3-oxo-butyrate 
• 144060-67-3 ethyl 2-(4-hydroxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate 

Downstream Products

• 144060-96-8 2-(3-bromo-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester 
• 160844-75-7 2-(3-cyano-4-isobutyloxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester 

Relevant articles and documents

PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE

Disclosed is a process for the preparation of Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate (I) the key intermediate for the preparation of [2-[3-cyano-4-(2-Methyl-propoxy)phenyl]-4-methyl-5-thiazole carboxylic acid (Febuxostat, I(A)) is approved under the trademark Uloric? by the US Food and Drug Administration for the treatment of hyperuricemia and gouty arthritis.

2-arylthiazole derivatives and pharmaceutical composition thereof

Pharmaceutical compositions for treating gout or hyperuricemia and containing a new categorized compound, i.e. 2-arylthiazole derivatives, as an active ingredient, are provided. The 2-arylthiazole derivatives in the present invention are represented by the following formula (I): STR1 wherein Ar is an unsubstituted or substituted pyridyl, thienyl, furyl, naphthyl or phenyl group; X is a hydrogen atom, alkyl group or carboxyl group which may be protected, and Y is a hydrogen atom, alkyl group, or a hydroxyl or carbonyl group which may be protected. Furthermore, novel compounds included in the 2-arylthiazole derivatives and pharmaceutically acceptable salts thereof are provided.